Holen Sie sich die Stockscreener-App
39.82
5.48%
2.07
Handel nachbörslich:
38.14
-1.68
-4.22%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TGTX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$37.75
Offen:
$37.25
24-Stunden-Volumen:
4.48M
Relative Volume:
1.80
Marktkapitalisierung:
$4.54B
Einnahmen:
$264.79M
Nettoeinkommen (Verlust:
$-14.36M
KGV:
-362.00
EPS:
-0.11
Netto-Cashflow:
$-28.11M
1W Leistung:
-2.38%
1M Leistung:
+32.34%
6M Leistung:
+77.93%
1J Leistung:
+175.76%
1-Tages-Spanne:
$37.05
$42.04
1-Wochen-Bereich:
$36.41
$42.04
52-Wochen-Spanne:
$12.93
$43.32
Tg Therapeutics Inc Stock (TGTX) Company Profile
Firmenname
Tg Therapeutics Inc
Sektor
Branche
Telefon
(212) 554-4484
Adresse
2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY
Vergleichen Sie TGTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TGTX
Tg Therapeutics Inc
|
39.82 | 4.54B | 264.79M | -14.36M | -28.11M | -0.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Tg Therapeutics Inc Stock (TGTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-29 | Eingeleitet | TD Cowen | Buy |
| 2023-08-02 | Hochstufung | Goldman | Sell → Neutral |
| 2023-06-26 | Fortgesetzt | Jefferies | Buy |
| 2022-05-20 | Eingeleitet | BofA Securities | Underperform |
| 2022-02-23 | Bestätigt | B. Riley Securities | Buy |
| 2021-11-15 | Herabstufung | Goldman | Neutral → Sell |
| 2021-04-20 | Eingeleitet | Goldman | Neutral |
| 2021-04-19 | Bestätigt | H.C. Wainwright | Buy |
| 2020-09-01 | Eingeleitet | JP Morgan | Overweight |
| 2020-08-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-05 | Eingeleitet | Evercore ISI | Outperform |
| 2020-01-17 | Bestätigt | H.C. Wainwright | Buy |
| 2019-11-27 | Fortgesetzt | B. Riley FBR | Buy |
| 2019-02-06 | Fortgesetzt | Jefferies | Buy |
| 2018-09-25 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2018-03-09 | Bestätigt | B. Riley FBR, Inc. | Buy |
| 2017-12-01 | Fortgesetzt | B. Riley FBR, Inc. | Buy |
| 2017-11-14 | Fortgesetzt | H.C. Wainwright | Buy |
| 2017-04-25 | Eingeleitet | Jefferies | Buy |
| 2017-03-06 | Bestätigt | FBR & Co. | Outperform |
| 2016-10-06 | Fortgesetzt | Brean Capital | Buy |
| 2016-05-27 | Eingeleitet | SunTrust | Buy |
| 2015-12-01 | Eingeleitet | FBR Capital | Outperform |
| 2015-09-09 | Eingeleitet | Raymond James | Strong Buy |
| 2015-08-12 | Fortgesetzt | H.C. Wainwright | Buy |
| 2015-06-19 | Bestätigt | Brean Capital | Buy |
| 2014-12-11 | Bestätigt | ROTH Capital | Buy |
| 2014-12-10 | Bestätigt | ROTH Capital | Buy |
Alle ansehen
Tg Therapeutics Inc Aktie (TGTX) Neueste Nachrichten
(TGTX) Technical Pivots with Risk Controls - news.stocktradersdaily.com
TGTX Gains as Roche's Ocrevus Fails in Phase 3 Trial; Impacting MS Market Dynamics - GuruFocus
TG Therapeutics stock rises as Roche’s trial fails (TGTX) - Seeking Alpha
CRUCIAL INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against TG Therapeutics, Inc. and Strongly Advises Investors with Losses to Contact the Firm - ACCESS Newswire
Should We Be Cautious About TG Therapeutics, Inc.'s (NASDAQ:TGTX) ROE Of 11%? - Yahoo Finance
Strength Seen in TG Therapeutics (TGTX): Can Its 10.2% Jump Turn into More Strength? - MSN
Why TG Therapeutics Stock Was Soaring This Week - MSN
Based On Its ROE, Is TG Therapeutics, Inc. (NASDAQ:TGTX) A High Quality Stock? - simplywall.st
(TGTX) Investment Analysis and Advice - Stock Traders Daily
TG Therapeutics stock soars to 52-week high of $43.03 By Investing.com - Investing.com South Africa
TG Therapeutics stock soars to 52-week high of $43.03 - Investing.com India
TG Therapeutics (TGTX) technical analysisTG Therapeutics (NASDAQ:TGTX) - Benzinga
TG Therapeutics (TGTX): Among the Best Short Squeeze Stocks to Buy According to Analysts - Yahoo Finance
Multiple Sclerosis Treatment Market 2034: EMA, PDMA, FDA Approval, Clinical Trials, Medication, Epidemiology, Prevalence, Therapies and Companies by DelveInsight - The Globe and Mail
Precision & TG Therapeutics: Unlocking Value With ARCUS, BRIUMVI And Azer-Cel (NASDAQ:DTIL) - Seeking Alpha
TG Therapeutics stock soars to 52-week high of $40.32 By Investing.com - Investing.com Australia
TG Therapeutics: Bright Outlook, Bolstered By Briumvi And Upcoming Trials (NASDAQ:TGTX) - Seeking Alpha
TG Therapeutics stock soars to 52-week high of $40.32 - Investing.com India
TG Therapeutics Stock (TGTX): Advancing MS Treatment - Value The Markets
Is TG Therapeutics, Inc. (TGTX) the Best Performing Growth Stock in 2025? - Insider Monkey
(TGTX) Technical Data - Stock Traders Daily
TG Therapeutics: Exciting Briumvi Performance, Looking To Re-Enter (NASDAQ:TGTX) - Seeking Alpha
10 Best Performing Growth Stocks in 2025 - Insider Monkey
Proficio Capital Partners LLC Buys Shares of 10,174 TG Therapeutics, Inc. (NASDAQ:TGTX) - Defense World
TG Therapeutics call volume above normal and directionally bullish - TipRanks
Smartleaf Asset Management LLC Has $60,000 Stock Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX) - Defense World
TG Therapeutics (NasdaqCM:TGTX) Surges 28% Following US$23 Million Net Income Turnaround - Yahoo Finance
Bilibili, MARA And ZEEKR Are Among Top 8 Mid-Cap Gainers Last Week (Mar 3-Mar 7): Are The Others In Your Portfolio? - Benzinga
Bank of New York Mellon Corp Increases Stake in TG Therapeutics, Inc. (NASDAQ:TGTX) - Defense World
Q2 Earnings Forecast for TG Therapeutics Issued By B. Riley - Defense World
TGTX Surges on Strong Q4 Results and Briumvi Success - GuruFocus.com
Why TG Therapeutics Shares Are Soaring Now - TipRanks
Retail Bets TG Therapeutics Stock Can Sustain Post-Earnings Gains Throughout The Week - MSN
TG Therapeutics Announces Schedule of Data Presentations - GlobeNewswire
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting - Yahoo Finance
Q1 Earnings Forecast for TG Therapeutics Issued By B. Riley - Defense World
This Biotech Stock Hits Buy Point After Earnings Burst - MSN
HC Wainwright Reaffirms “Buy” Rating for TG Therapeutics (NASDAQ:TGTX) - Defense World
TG Therapeutics FY2025 EPS Estimate Boosted by HC Wainwright - Defense World
Why TG Therapeutics, Inc. (TGTX) Surged On Monday? - MSN
TG Therapeutics, Inc. (NASDAQ:TGTX) Holdings Decreased by Private Advisor Group LLC - Defense World
TG Therapeutics (NASDAQ:TGTX) Upgraded by StockNews.com to Hold Rating - Defense World
TG Therapeutics (NASDAQ:TGTX) Shares Up 5.2% After Earnings Beat - Defense World
TG Therapeutics, Inc. (NASDAQ:TGTX) Q4 2024 Earnings Call Transcript - MSN
TG Therapeutics Target of Unusually Large Options Trading (NASDAQ:TGTX) - Defense World
TG Therapeutics, A New Leaderboard Stock, Skyrockets 17% On Sales Beat, Bullish Guide - MSN
TG Therapeutics stock soars to 52-week high of $36.89 By Investing.com - Investing.com South Africa
TG Therapeutics stock soars to 52-week high of $36.89 - Investing.com India
Finanzdaten der Tg Therapeutics Inc-Aktie (TGTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):